Articles tagged with: Carfilzomib

News»

[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immunotherapeutic approach to treating cancer …

Read the full story »

News»

[ by | Dec 8, 2014 7:02 am | 5 Comments ]
ASH 2014 Multiple Myeloma Update – Day One: Poster Session

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of interesting pre­sen­ta­tions about multiple myeloma.

Oral presentations about new treatments under development were given mid-day and were summarized in a Beacon ASH Daily Update published yesterday morning.

During Saturday evening, a poster session took place where important new research findings were summarized in posters displayed throughout two separate large conference halls.

The studies covered a variety of myeloma-related topics, ranging from new treatments being developed for myeloma, …

Read the full story »

News»

[ by | Dec 7, 2014 9:07 am | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day One: Oral Sessions

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in San Francisco.

Myeloma-related presentations were made during several sessions throughout the day.

The day started out with a session designed to better educate physicians about multiple myeloma and how to treat the disease.

Two sessions of oral presentations devoted solely to multiple myeloma ran simultaneously in the middle of the day. One of the sessions focused on the biology of the disease. The other one included presentations on new myeloma therapies for both newly diagnosed and …

Read the full story »

News»

[ by | Aug 17, 2014 4:10 pm | 5 Comments ]
Kyprolis Fails To Provide Overall Survival Benefit In FOCUS Phase 3 Trial

Amgen has given a first glimpse of key results from its FOCUS Phase 3 clinical trial testing Kyprolis in relapsed and refractory multiple myeloma patients.

The company reported this past Wednesday that Kyprolis did not provide an overall survival advantage in the trial, which is being con­ducted out­side the United States.

In addition, the company noted that patients treated with Kyprolis during the trial experienced more kidney-related side effects than patients who were not treated with the drug.

Up until recently, the primary significance of the FOCUS trial would have …

Read the full story »

News»

[ by | Aug 4, 2014 6:51 pm | 16 Comments ]
Kyprolis Succeeds In Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Planned For Europe And Other Countries

Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial com­par­ing Kyprolis-Revlimid-dex­a­meth­a­sone to Revlimid-dex­a­meth­a­sone in pa­tients with relapsed multiple myeloma.

Patients in the trial who received the Kyprolis-Revlimid-dex­a­meth­a­sone com­bi­na­tion (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dex­a­meth­a­sone (Rd) (17.6 months).

There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. How­ever, the difference is not yet statistically significant.

The results of the trial are important for two …

Read the full story »